Augere Medical

Augere Medical is a private, clinical-stage medical device and digital health company focused on transforming colorectal cancer screening with its AI platform, PolypAID™. The company has raised NOK 73 million (approx. USD 6.6M) from a mix of public grants and private investors, including AM Equity and MP Pensjon, and is advancing its platform through clinical validation and regulatory pathways. With a strong foundation in research from Simula and leading Scandinavian hospitals, Augere aims to reduce missed polyps and interval cancers by providing real-time, high-accuracy decision support to gastroenterologists.

PolypAID™: An AI-powered real-time computer-aided detection (CADe) platform for colonoscopy. It uses machine learning algorithms trained on a proprietary database of over 2 million annotated image frames to detect and highlight polyps (adenomas, sessile serrated lesions, hyperplastic) with high sensitivity and specificity, aiming to reduce missed rates.

The AI-assisted colonoscopy market is competitive, featuring large players like Medtronic (GI Genius) and Olympus, as well as numerous other startups. Differentiation is based on algorithm accuracy, false positive rates, user interface, and clinical validation. Augere positions itself on its proprietary dataset, transparent AI confidence indicator, and agility derived from its research-focused origins.